KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbCellera Biologics (ABCL) Operating Income (2020 - 2026)

AbCellera Biologics filings provide 7 years of Operating Income readings, the most recent being -$57.5 million for Q1 2026.

  • Quarterly Operating Income rose 8.2% to -$57.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$212.0 million through Mar 2026, up 34.28% year-over-year, with the annual reading at -$217.1 million for FY2025, 31.03% up from the prior year.
  • Operating Income hit -$57.5 million in Q1 2026 for AbCellera Biologics, down from -$28.6 million in the prior quarter.
  • Across five years, Operating Income topped out at $225.0 million in Q1 2022 and bottomed at -$93.7 million in Q3 2024.
  • Average Operating Income over 5 years is -$35.9 million, with a median of -$54.9 million recorded in 2024.
  • The largest annual shift saw Operating Income surged 234.31% in 2022 before it crashed 512.07% in 2023.
  • AbCellera Biologics' Operating Income stood at -$37.8 million in 2022, then crashed by 74.85% to -$66.1 million in 2023, then fell by 10.15% to -$72.8 million in 2024, then skyrocketed by 60.71% to -$28.6 million in 2025, then plummeted by 101.24% to -$57.5 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Operating Income are -$57.5 million (Q1 2026), -$28.6 million (Q4 2025), and -$76.3 million (Q3 2025).